SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.
Related Questions
What is the company's cash burn rate and runway given the reported cash position?
Are there any upcoming financing events, such as equity offerings or debt issuances, that could dilute shareholders?
Did the company meet or exceed its revenue guidance for the quarter, and what does that imply for future earnings?
How does the company's R&D spending trend compare to industry norms and what does that mean for future growth?
What is the risk of dilution from potential convertible securities or options outstanding?
What is the projected timeline for any upcoming regulatory filings or approvals?
How will the reported Q2 2025 financial results affect CLDI's stock price in the short term?
Are there any upcoming clinical trial milestones that could significantly move the stock price?
How might the recent operational highlights influence the company's competitive positioning?
What is the status of the company's pipeline, especially the lead candidate, and its potential market impact?
How does CLDI's valuation (P/E, EV/EBITDA, etc.) compare with peer biotech companies?
What are the details of the recent operational highlights and how might they impact future cash flows?
What are the analysts' consensus estimates for CLDI's Q3 and full-year 2025 earnings, and how does this release affect those estimates?
How does the current cash position compare to the company's projected operating expenses for the next 12 months?